Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.40)
# 890
Out of 4,667 analysts
425
Total ratings
42.65%
Success rate
5.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Reiterates: Buy | $50 | $30.98 | +61.41% | 22 | Nov 18, 2024 | |
| ABUS Arbutus Biopharma | Reiterates: Buy | $5 | $3.48 | +43.67% | 17 | Nov 18, 2024 | |
| SGMT Sagimet Biosciences | Reiterates: Buy | $32 | $4.35 | +636.48% | 9 | Nov 15, 2024 | |
| GALT Galectin Therapeutics | Reiterates: Buy | $11 | $2.75 | +300.00% | 15 | Nov 15, 2024 | |
| UNCY Unicycive Therapeutics | Maintains: Buy | $2.5 → $4 | $0.49 | +716.33% | 23 | Nov 14, 2024 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $12 | $1.66 | +625.08% | 13 | Nov 14, 2024 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $0.96 | - | 12 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Buy | $66 | $42.31 | +55.99% | 29 | Nov 13, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Neutral | $5.5 → $7.5 | $5.83 | +28.64% | 10 | Nov 13, 2024 | |
| CDTX Cidara Therapeutics | Reiterates: Buy | $24 | $15.63 | +53.55% | 21 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $7.91 | +266.74% | 20 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5.5 | $4.71 | +16.77% | 7 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $12.46 | +204.98% | 20 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $63 | $17.39 | +262.28% | 24 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $18.22 | +311.64% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $95 | $45.25 | +109.94% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7.5 | $1.81 | +314.36% | 32 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $390 | $313.61 | +24.36% | 15 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $2.74 | +374.45% | 13 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.28 | +203.64% | 17 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $9.21 | +193.16% | 9 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $18 | $17.19 | +4.71% | 19 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $15.34 | - | 6 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.61 | +210.56% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $7.99 | +62.70% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $6 | $0.69 | +770.83% | 4 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 → $240 | $1.13 | +21,137.06% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.36 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $45.90 | -45.53% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.05 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $19.63 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13,500 → $14,625 | $2.02 | +723,909.90% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $51.23 | -86.34% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $29.51 | -28.84% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.12 | - | 2 | Feb 15, 2017 |
Akero Therapeutics
Nov 18, 2024
Reiterates: Buy
Price Target: $50
Current: $30.98
Upside: +61.41%
Arbutus Biopharma
Nov 18, 2024
Reiterates: Buy
Price Target: $5
Current: $3.48
Upside: +43.67%
Sagimet Biosciences
Nov 15, 2024
Reiterates: Buy
Price Target: $32
Current: $4.35
Upside: +636.48%
Galectin Therapeutics
Nov 15, 2024
Reiterates: Buy
Price Target: $11
Current: $2.75
Upside: +300.00%
Unicycive Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $2.5 → $4
Current: $0.49
Upside: +716.33%
Acurx Pharmaceuticals
Nov 14, 2024
Reiterates: Buy
Price Target: $12
Current: $1.66
Upside: +625.08%
DURECT
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.96
Upside: -
Mirum Pharmaceuticals
Nov 13, 2024
Reiterates: Buy
Price Target: $66
Current: $42.31
Upside: +55.99%
Terns Pharmaceuticals
Nov 13, 2024
Maintains: Neutral
Price Target: $5.5 → $7.5
Current: $5.83
Upside: +28.64%
Cidara Therapeutics
Nov 11, 2024
Reiterates: Buy
Price Target: $24
Current: $15.63
Upside: +53.55%
Nov 11, 2024
Reiterates: Buy
Price Target: $29
Current: $7.91
Upside: +266.74%
Nov 11, 2024
Downgrades: Neutral
Price Target: $5.5
Current: $4.71
Upside: +16.77%
Nov 8, 2024
Reiterates: Buy
Price Target: $38
Current: $12.46
Upside: +204.98%
Nov 8, 2024
Reiterates: Buy
Price Target: $63
Current: $17.39
Upside: +262.28%
Nov 7, 2024
Reiterates: Buy
Price Target: $75
Current: $18.22
Upside: +311.64%
Nov 6, 2024
Maintains: Buy
Price Target: $82 → $95
Current: $45.25
Upside: +109.94%
Oct 23, 2024
Reiterates: Buy
Price Target: $7.5
Current: $1.81
Upside: +314.36%
Oct 22, 2024
Reiterates: Buy
Price Target: $390
Current: $313.61
Upside: +24.36%
Oct 15, 2024
Maintains: Buy
Price Target: $14 → $13
Current: $2.74
Upside: +374.45%
Oct 11, 2024
Reiterates: Buy
Price Target: $13
Current: $4.28
Upside: +203.64%
Oct 10, 2024
Reiterates: Buy
Price Target: $27
Current: $9.21
Upside: +193.16%
Sep 27, 2024
Maintains: Buy
Price Target: $23 → $18
Current: $17.19
Upside: +4.71%
Sep 24, 2024
Reiterates: Neutral
Price Target: n/a
Current: $15.34
Upside: -
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $1.61
Upside: +210.56%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $7.99
Upside: +62.70%
Aug 16, 2024
Reiterates: Buy
Price Target: $6
Current: $0.69
Upside: +770.83%
Mar 26, 2024
Reiterates: Buy
Price Target: $12 → $240
Current: $1.13
Upside: +21,137.06%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.36
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $45.90
Upside: -45.53%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $3.05
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $19.63
Upside: -
May 12, 2020
Maintains: Buy
Price Target: $13,500 → $14,625
Current: $2.02
Upside: +723,909.90%
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $51.23
Upside: -86.34%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $29.51
Upside: -28.84%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.12
Upside: -